Mushtaq Ahmad Wani

Dr. Mushtaq Ahmad Wani

Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, Mohali, India
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
SSSupriya Sharma
Supriya Sharma
SWSharad Wakode
Sharad Wakode
ASAnjali Sharma
Anjali Sharma
NNNisha Nair
Nisha Nair
MDMahaveer Dhobi
Mahaveer Dhobi
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo

11 October 2021 in Medical & Biological Engineering & Computing
Verified
Journal Article
Closed access
PDF file
Mushtaq Ahmad WaniMushtaq Ahmad Wani
Mushtaq Ahmad Wani
PGPrabha Garg
Prabha Garg
KKKuldeep Kumar
Kuldeep Kumar

27 November 2019 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
KKKuldeep Kumar
Kuldeep Kumar
Mushtaq Ahmad WaniMushtaq Ahmad Wani
Mushtaq Ahmad Wani
Introduction: Tuberculosis (TB) is a leading infectious disease worldwide whose chemotherapy is challenged by the continued rise of drug resistance. This epidemic urges the need to discover anti-TB drugs with novel modes of action. Areas covered: The mycobacterial electron transport chain (ETC) pathway represents a hub of anti-TB drug targets. Herein, the authors highlight the various targets within the mycobacterial ETC and highlight some of the promising ETC-targeted drugs and clinical candidates that have been discovered or repurposed. Furthermore, recent breakthroughs in the availability of X-ray and/or cryo-EM structures of some targets are discussed, and various opportunities of exploiting these structures for the discovery of new anti-TB drugs are emphasized. Expert opinion: The drug discovery efforts targeting the ETC pathway have led to the FDA approval of bedaquiline, a FOF1-ATP synthase inhibitor, and the discovery of Q203, a clinical candidate drug targeting the mycobacterial cytochrome bcc-aa3 supercomplex. Moreover, clofazimine, a proposed prodrug competing with menaquinone for its reduction by mycobacterial NADH dehydrogenase 2, has been repurposed for TB treatment. Recently available structures of the mycobacterial ATP synthase C9 rotary ring and the cytochrome bcc-aa3 supercomplex represent further opportunities for the structure-based drug design (SBDD) of the next-generation of inhibitors against Mycobacterium tuberculosis.


25 April 2023 in Progress in Biophysics and Molecular Biology
Verified
Journal Article
Closed access
LKLakshmi Mounika Kelam
Lakshmi Mounika Kelam
Mushtaq Ahmad WaniMushtaq Ahmad Wani
Mushtaq Ahmad Wani
DDDevendra K. Dhaked
Devendra K. Dhaked

11 November 2021 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
Mushtaq Ahmad WaniMushtaq Ahmad Wani
Mushtaq Ahmad Wani
DDDevendra Kumar Dhaked
Devendra Kumar Dhaked